A detailed history of Vanguard Group Inc transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,022,790 shares of STRO stock, worth $8.86 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,022,790
Previous 2,890,000 4.59%
Holding current value
$8.86 Million
Previous $12.4 Million 37.75%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$3.27 - $5.65 $434,223 - $750,263
132,790 Added 4.59%
3,022,790 $17.1 Million
Q4 2023

Feb 14, 2024

BUY
$2.07 - $4.54 $43,962 - $96,420
21,238 Added 0.74%
2,890,000 $12.4 Million
Q3 2023

Nov 14, 2023

BUY
$3.29 - $4.9 $127,829 - $190,384
38,854 Added 1.37%
2,868,762 $9.95 Million
Q2 2023

Aug 14, 2023

BUY
$4.25 - $5.88 $225,020 - $311,322
52,946 Added 1.91%
2,829,908 $13.2 Million
Q1 2023

May 15, 2023

BUY
$4.48 - $8.45 $592,659 - $1.12 Million
132,290 Added 5.0%
2,776,962 $12.8 Million
Q4 2022

Feb 10, 2023

BUY
$5.41 - $8.08 $3.22 Million - $4.8 Million
594,396 Added 28.99%
2,644,672 $21.4 Million
Q3 2022

Nov 14, 2022

BUY
$5.17 - $7.11 $66,956 - $92,081
12,951 Added 0.64%
2,050,276 $11.4 Million
Q2 2022

Aug 12, 2022

SELL
$3.41 - $8.95 $660,421 - $1.73 Million
-193,672 Reduced 8.68%
2,037,325 $10.6 Million
Q1 2022

May 13, 2022

BUY
$7.78 - $15.31 $880,618 - $1.73 Million
113,190 Added 5.34%
2,230,997 $18.3 Million
Q4 2021

Feb 14, 2022

BUY
$14.25 - $23.53 $39,558 - $65,319
2,776 Added 0.13%
2,117,807 $31.5 Million
Q3 2021

Nov 12, 2021

BUY
$16.88 - $22.38 $874,991 - $1.16 Million
51,836 Added 2.51%
2,115,031 $40 Million
Q2 2021

Aug 13, 2021

BUY
$18.03 - $23.82 $37.2 Million - $49.1 Million
2,063,195 New
2,063,195 $38.4 Million

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $153M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.